{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:45:05Z","timestamp":1792251905144,"version":"4.4.0"},"reference-count":101,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) is increasingly recognized as a central component of cardiovascular\u2013kidney\u2013metabolic syndrome, reflecting shared pathways of insulin resistance, inflammation, and fibrotic injury that drive multiorgan disease. Affecting more than one third of adults worldwide, MASLD frequently coexists with CKD and cardiovascular disease and is associated with higher risks of kidney function decline, cardiovascular (CV) events, and mortality. Hepatic steatosis and fibrosis may amplify systemic metabolic stress and endothelial dysfunction, contributing to progressive kidney injury and adverse cardiometabolic outcomes. Despite this biologic and epidemiologic overlap, MASLD remains underrecognized in nephrology and cardiology practice. This gap represents a missed opportunity to identify patients at a high risk of multiorgan complications early. Noninvasive liver fibrosis assessment, integrated with kidney and CV risk stratification, offers a practical approach to identifying patients who may benefit from intensified preventive strategies. Lifestyle modification remains foundational, while emerging pharmacotherapies, including glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and liver-directed agents, demonstrate potential cross-organ benefits. Coordinated management targeting metabolic dysfunction may slow the progression of kidney disease while improving hepatic and CV outcomes. This review highlights the clinical intersection of MASLD, CKD, and cardiovascular disease and proposes a multidisciplinary framework for screening and management. Recognizing MASLD as part of systemic cardiovascular\u2013kidney\u2013metabolic disease can inform risk stratification, guide therapy selection, and support earlier intervention to mitigate the triple burden of liver, kidney, and CV complications.<\/jats:p>","DOI":"10.2215\/cjn.0000001209","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:47Z","timestamp":1786118447000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Dysfunction\u2013Associated Steatotic Liver Disease, Cardiovascular, and Kidney Disease"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3438-0644","authenticated-orcid":false,"given":"Stephanie Y.","family":"Tsai","sequence":"first","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle B.","family":"Uwera","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-4651","authenticated-orcid":false,"given":"Bethany","family":"Roehm","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-2573","authenticated-orcid":false,"given":"Lisa B.","family":"VanWagner","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"5","key":"B1-20261017","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of liver diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology."},{"issue":"6","key":"B2-20261017","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol."},{"issue":"11","key":"B3-20261017","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","author":"Tacke","year":"2024","journal-title":"Diabetologia."},{"issue":"3","key":"B4-20261017","doi-asserted-by":"crossref","first-page":"100597","DOI":"10.1016\/j.xkme.2022.100597","article-title":"CKD-associated cardiovascular mortality in the United States: temporal trends from 1999 to 2020","volume":"5","author":"Kobo","year":"2023","journal-title":"Kidney Med."},{"issue":"13","key":"B5-20261017","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"suppl l","key":"B6-20261017","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol."},{"issue":"20","key":"B7-20261017","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"20","key":"B8-20261017","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"6","key":"B9-20261017","first-page":"e85813","article-title":"Cardiovascular-renal-hepatic-metabolic syndrome: interlinked pathophysiology and integrated management approach","volume":"17","author":"Arragan Lezama","year":"2025","journal-title":"Cureus."},{"issue":"3","key":"B10-20261017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/biom15030373","article-title":"Cardiovascular\u2013endocrine\u2013metabolic medicine: proposing a new clinical sub-specialty amid the cardiometabolic pandemic","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules."},{"issue":"9","key":"B11-20261017","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/biomedicines13092162","article-title":"Metabolic dysfunction-associated steatotic liver disease as a risk factor for chronic kidney disease: a narrative review","volume":"13","author":"Souto Maior","year":"2025","journal-title":"Biomedicines."},{"issue":"21","key":"B12-20261017","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA."},{"issue":"11","key":"B13-20261017","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"5","key":"B14-20261017","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/HEP.0000000000001211","article-title":"Prevalence of metabolic dysfunction\u2013associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data","volume":"82","author":"Unalp-Arida","year":"2025","journal-title":"Hepatology."},{"issue":"5","key":"B15-20261017","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.kint.2024.12.021","article-title":"The prevention and management of chronic kidney disease among patients with metabolic syndrome","volume":"107","author":"Zhu","year":"2025","journal-title":"Kidney Int."},{"key":"B16-20261017","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.2147\/DMSO.S569698","article-title":"Metabolic dysfunction-associated steatotic liver disease and liver fibrosis are associated with advanced cardiovascular-kidney-metabolic syndrome in Chinese and US populations","volume":"18","author":"Hu","year":"2025","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"B17-20261017","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab."},{"issue":"1","key":"B18-20261017","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41598-018-23014-0","article-title":"Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study","volume":"8","author":"Jang","year":"2018","journal-title":"Scientific Rep."},{"issue":"1","key":"B19-20261017","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut."},{"issue":"9","key":"B20-20261017","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/MEG.0000000000001169","article-title":"Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis","volume":"30","author":"Wijarnpreecha","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"4","key":"B21-20261017","doi-asserted-by":"crossref","first-page":"630","DOI":"10.4093\/dmj.2021.0130","article-title":"Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Seo","year":"2022","journal-title":"Diabetes Metab J."},{"issue":"12 Pt 2","key":"B22-20261017","doi-asserted-by":"crossref","first-page":"102369","DOI":"10.1016\/j.jacadv.2025.102369","article-title":"Cardiovascular-kidney-metabolic syndrome-attributable mortality in the United States, from 2010 to 2023","volume":"4","author":"Zuin","year":"2025","journal-title":"JACC Adv."},{"key":"B23-20261017","doi-asserted-by":"crossref","first-page":"101369","DOI":"10.1016\/j.ajpc.2025.101369","article-title":"Cardiovascular-kidney-metabolic syndrome stages and increased risk of all-cause and cause-specific mortality in UK Biobank","volume":"25","author":"Xu","year":"2026","journal-title":"Am J Prev Cardiol"},{"issue":"7","key":"B24-20261017","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1681\/ASN.0000000637","article-title":"Cumulative incidence of mortality associated with cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome","volume":"36","author":"Claudel","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"B25-20261017","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut."},{"issue":"2","key":"B26-20261017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2023","journal-title":"Gut."},{"issue":"7","key":"B27-20261017","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease","volume":"19","author":"Meyersohn","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"B28-20261017","doi-asserted-by":"crossref","first-page":"e014279","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"Vanwagner","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"10","key":"B29-20261017","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol."},{"issue":"2","key":"B30-20261017","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12664-025-01833-0","article-title":"Sex and gender differences in metabolic dysfunction-associated liver disease","volume":"45","author":"Penmetsa","year":"2026","journal-title":"Indian J Gastroenterol."},{"issue":"3","key":"B31-20261017","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/oby.23960","article-title":"Noninvasive tests to identify liver fibrosis in metabolic dysfunction\u2010associated steatotic liver disease are affected by race","volume":"32","author":"Bril","year":"2024","journal-title":"Obesity."},{"issue":"9","key":"B32-20261017","doi-asserted-by":"crossref","first-page":"102084","DOI":"10.1016\/j.jacadv.2025.102084","article-title":"Social determinants of health and mortality in cardiovascular-kidney-metabolic syndrome","volume":"4","author":"Chang","year":"2025","journal-title":"JACC Adv."},{"issue":"9","key":"B33-20261017","doi-asserted-by":"crossref","first-page":"sfaf260","DOI":"10.1093\/ckj\/sfaf260","article-title":"The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management","volume":"18","author":"Moncho","year":"2025","journal-title":"Clin Kidney J."},{"key":"B34-20261017","doi-asserted-by":"crossref","first-page":"1661563","DOI":"10.3389\/fcvm.2025.1661563","article-title":"Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome","volume":"12","author":"Nzobokela","year":"2025","journal-title":"Front Cardiovasc Med."},{"key":"B35-20261017","doi-asserted-by":"crossref","first-page":"1119005","DOI":"10.3389\/fcvm.2023.1119005","article-title":"The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease","volume":"10","author":"Qin","year":"2023","journal-title":"Front Cardiovasc Med."},{"issue":"10","key":"B36-20261017","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"B37-20261017","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B38-20261017","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1681\/ASN.2010121220","article-title":"Colonic contribution to uremic solutes","volume":"22","author":"Aronov","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B39-20261017","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1681\/ASN.2015121302","article-title":"Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD","volume":"27","author":"Poesen","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B40-20261017","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1681\/ASN.0000000000000344","article-title":"The gut microbial metabolite trimethylamine N-oxide, incident CKD, and kidney function decline","volume":"35","author":"Wang","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B41-20261017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.27643","article-title":"PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease","volume":"62","author":"Musso","year":"2015","journal-title":"Hepatology."},{"issue":"5","key":"B42-20261017","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology."},{"issue":"12","key":"B43-20261017","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"B44-20261017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","article-title":"The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J Clin Gastroenterol."},{"issue":"3","key":"B45-20261017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HEP.0000000000001346","article-title":"Organ damage proteomic signature identifies patients with MASLD at risk of systemic complications","volume":"83","author":"Pirola","year":"2026","journal-title":"Hepatology."},{"issue":"12","key":"B46-20261017","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.14309\/ajg.0000000000003421","article-title":"Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis","volume":"120","author":"Abu-Rumaileh","year":"2025","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"B47-20261017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia."},{"issue":"25","key":"B48-20261017","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.jacc.2025.09.1602","article-title":"The heart-brain-metabolism axis in cardiovascular and neurologic disease","volume":"86","author":"Tardo","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"24","key":"B49-20261017","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation."},{"issue":"suppl ment_1","key":"B50-20261017","first-page":"S61","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care."},{"issue":"1","key":"B51-20261017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation."},{"issue":"1","key":"B52-20261017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical care pathway for the risk stratification and management of patients with metabolic dysfunction\u2013associated steatotic liver disease","volume":"171","author":"Kanwal","year":"2026","journal-title":"Gastroenterology."},{"issue":"5","key":"B53-20261017","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"issue":"5","key":"B54-20261017","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology."},{"issue":"7","key":"B55-20261017","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care."},{"issue":"16","key":"B56-20261017","doi-asserted-by":"crossref","first-page":"e043173","DOI":"10.1161\/JAHA.125.043173","article-title":"Incorporation of metabolic dysfunction associated steatotic liver disease in the health stage of cardiovascular kidney metabolic syndrome improves predictive ability for coronary artery disease in a Japanese general population","volume":"14","author":"Kawaharata","year":"2025","journal-title":"J Am Heart Assoc."},{"issue":"5","key":"B57-20261017","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease\u2010specific mortality in NAFLD after up to 33 years of follow up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology."},{"issue":"4","key":"B58-20261017","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol."},{"issue":"5","key":"B59-20261017","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","article-title":"Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","volume":"83","author":"Tavaglione","year":"2025","journal-title":"J Hepatol."},{"issue":"7","key":"B60-20261017","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1681\/ASN.0000001005","article-title":"Clinical implications of missed CKD diagnosis in adults with and without diabetes mellitus","volume":"37","author":"Levin-Iaina","year":"2026","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B61-20261017","doi-asserted-by":"crossref","first-page":"e0829","DOI":"10.1097\/HC9.0000000000000829","article-title":"Low awareness of MASLD among U.S. adults: trends from NHANES 2017\u20132023","volume":"9","author":"Alp","year":"2025","journal-title":"Hepatol Commun."},{"issue":"5","key":"B62-20261017","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.clnu.2020.12.009","article-title":"Effectiveness of dietetic intervention for people with type 2 diabetes: a meta-analysis","volume":"40","author":"Siopis","year":"2021","journal-title":"Clin Nutr."},{"issue":"4","key":"B63-20261017","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1017\/S1368980019002568","article-title":"Adherence to the dietary approaches to stop hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults","volume":"23","author":"Xiao","year":"2020","journal-title":"Public Health Nutr."},{"issue":"5","key":"B64-20261017","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.clnu.2020.10.058","article-title":"Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study","volume":"40","author":"Kouvari","year":"2021","journal-title":"Clin Nutr."},{"issue":"2","key":"B65-20261017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ekir.2024.10.032","article-title":"Randomized trial of dietary acid reduction and acid-base status of patients with CKD and normal estimated GFR","volume":"10","author":"Goraya","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"18","key":"B67-20261017","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2018.16789","article-title":"Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA."},{"issue":"3","key":"B68-20261017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.32642","article-title":"Metabolic dysfunction associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality","volume":"77","author":"van Kleef","year":"2023","journal-title":"Hepatology."},{"issue":"6","key":"B69-20261017","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.numecd.2022.02.012","article-title":"Alcohol consumption and its association with chronic kidney disease: evidence from a 12-year China health and nutrition survey","volume":"32","author":"Li","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"5","key":"B70-20261017","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2025.07.019","article-title":"Phosphatidylethanol in steatotic liver disease","volume":"83","author":"Torp","year":"2025","journal-title":"J Hepatol."},{"issue":"1","key":"B100-20261017","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun."},{"issue":"3","key":"B101-20261017","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol."},{"issue":"6","key":"B71-20261017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"B72-20261017","first-page":"e70859","article-title":"Effectiveness of resmetirom in reducing cholesterol levels in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"16","author":"Bejitual","year":"2024","journal-title":"Cureus."},{"issue":"10","key":"B73-20261017","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"B74-20261017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract."},{"issue":"11","key":"B75-20261017","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care."},{"issue":"2","key":"B76-20261017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"21","key":"B77-20261017","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med."},{"issue":"5","key":"B78-20261017","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction\u2013associated steatohepatitis: november 2025 updates to AASLD practice guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology."},{"issue":"4","key":"B79-20261017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med."},{"issue":"9","key":"B80-20261017","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med."},{"issue":"2","key":"B81-20261017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"key":"B82-20261017","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ."},{"issue":"4","key":"B83-20261017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med."},{"issue":"6","key":"B84-20261017","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.14670","article-title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","volume":"24","author":"Kahl","year":"2022","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"B85-20261017","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/ph18081118","article-title":"SGLT2 inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) associated with sustained hepatic benefits, besides the cardiometabolic","volume":"18","author":"Suki","year":"2025","journal-title":"Pharmaceuticals."},{"key":"B86-20261017","doi-asserted-by":"crossref","first-page":"112918","DOI":"10.1016\/j.diabres.2025.112918","article-title":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","volume":"229","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract."},{"issue":"25","key":"B87-20261017","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation."},{"issue":"18","key":"B88-20261017","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"issue":"3","key":"B89-20261017","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"issue":"20","key":"B90-20261017","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"issue":"9069","key":"B91-20261017","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet."},{"issue":"2","key":"B92-20261017","doi-asserted-by":"crossref","first-page":"e001294","DOI":"10.1136\/openhrt-2020-001294","article-title":"Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"7","author":"Nielsen","year":"2020","journal-title":"Open Heart."},{"issue":"1","key":"B93-20261017","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41598-021-81959-1","article-title":"Clinical implications of renin\u2013angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease","volume":"11","author":"Kim","year":"2021","journal-title":"Scientific Rep."},{"issue":"2","key":"B94-20261017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HEP.0000000000001333","article-title":"Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction\u2013associated steatotic liver diseases: target trial emulation using real-world data","volume":"83","author":"Ng","year":"2026","journal-title":"Hepatology."},{"issue":"23","key":"B95-20261017","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"B96-20261017","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/dom.15305","article-title":"Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: a FIDELITY subgroup analysis","volume":"26","author":"Perakakis","year":"2024","journal-title":"Diabetes Obes Metab."},{"issue":"9784","key":"B97-20261017","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"1","key":"B98-20261017","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","article-title":"Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Zhao","year":"2021","journal-title":"Ren Fail."},{"issue":"6","key":"B99-20261017","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta\u2010analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"B102-20261017","doi-asserted-by":"crossref","first-page":"100857","DOI":"10.1016\/j.gastha.2025.100857","article-title":"Unrecognized fibrosis risk in MASLD: a real-world analysis and the case for AI-augmented stratification","volume":"5","author":"Ebiai","year":"2026","journal-title":"Gastro Hep Adv."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:01:24Z","timestamp":1792249284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001209"}},"subtitle":["Triple Challenges"],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":101,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001209","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}